Alnylam Pharmaceuticals, Inc. (ALNY) earnings on October 29, 2026
More Alnylam Pharmaceuticals, Inc. earnings
Prior outlook: Optimistic Outcome: Missed
Alnylam shares closed 25.13% lower after quarterly results and a Phase 3 TRITON-CM study update caused a sharp selloff.
ALNY price around the earnings
174.00
Change: -25.1%
2026-10-29, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Missed
- Thesis published
- Results released
The price setup carries the optimistic view, supported by analyst price targets far above current market review levels and positive clinical headlines. Market sentiment is more cautious, and a sharp drop after recent company results tempers the picture.
Context analyzed before publication
- Playbook
- The average analyst price target sits roughly 58% above current levels, while the stock has recently lagged the broader technology index. Past reactions to company results have been unusually sharp, so swings around results have historically been large.
- Trend
- Growth expectations hold, but weaker confidence keeps the scenario cautiously optimistic.
Analysts
Drivers
-
Analysts
Positive
The average analyst price target of $368 sits about 58% above the current price, based on 27 analyst opinions that are mostly favorable.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.67
- Analysts covering the stock
- 27
- Average price target
- 367.78
- Lowest price target
- 250
- Highest price target
- 536
- Upside to price target
- 58.3%
- Revenue growth
- 66.9%
- Forward EPS
- 12.35
- Trailing EPS
- 5.93
- Analyst moves in the last 60 days
- 7
- Strong buy: 6
- Buy: 17
- Hold: 7
- Sell: 0
- Strong sell: 0
- Strong buy
- 6
- Buy
- 17
- Hold
- 7
- Sell
- 0
- Strong sell
- 0
- October 14, 2026 · Citigroup: Maintains rating (Buy → Buy)
- October 14, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
- October 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- September 30, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
- September 21, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)
- September 8, 2026 · Jefferies: Maintains rating (Hold → Hold)
- September 2, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Positive
Phase 1b brezosiran headlines report reductions of up to 83% that grow with the dose, and the company plans further confirmatory study work.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
- Messages
- 30
News
Sources (8)
- Alnylam Announces Positive Initial Phase 1b Data for Brezosiran in Huntington's Disease (opens in a new tab) — fiscal.ai
- Alnylam Says Phase 1b Brezosiran Study Showed Dose-Dependent CSF Mutant Huntingtin Reductions, Up To 83% Individually, No Dose-Dependent Safety Signals; Pivotal Study Planned 2027 Pending Regulatory Alignment (opens in a new tab) — Benzinga
- Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320 (opens in a new tab) — Benzinga
- Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253 (opens in a new tab) — Benzinga
- If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today (opens in a new tab) — Benzinga
- RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345 (opens in a new tab) — Benzinga
- Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today (opens in a new tab) — Benzinga
- JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369 (opens in a new tab) — Benzinga
Technicals
Drivers
-
Technical
Negative
Over 30 days, the stock fell 8.95% while QQQ fell 1.49%, leaving it 7.46 points behind the technology index. In the last 14 days, it gained 3.56%, and the scenario points optimistic.
Evidence
- Price when the context was analyzed
- 232.5
- Average true range (ATR)
- 3.2%
- Distance to 52-week high
- -51.7%
- 14-day change (14d)
- +3.6%
- 30-day change (30d)
- -8.9%
- 30-day relative strength
- -7.5%
- QQQ change (30d)
- -1.5%
- Nearest support
- 232
- Distance to nearest support
- 0.2%
- Nearest resistance
- 236.88
- Distance to nearest resistance
- 1.9%
- Volume accumulation ratio (14d / 46d)
- 0.78
- Mid: 232 (0.2% away, 0.07 ATR, 34 touches)
- Major: 229.2 (1.4% away, 0.44 ATR, 48 touches)
- Mid: 225.65 (3% away, 0.91 ATR, 10 touches)
- Major: 236.88 (1.9% away, 0.58 ATR, 35 touches)
- Major: 239.1 (2.8% away, 0.88 ATR, 44 touches)
- Major: 242.65 (4.4% away, 1.35 ATR, 21 touches)
Trends
Evidence
- Average earnings surprise
- +17.7%
- July 30, 2026: actual EPS 1.84 vs estimate 2.14 (surprise -14.2%)
- April 30, 2026: actual EPS 1.99 vs estimate 1.47 (surprise +35.3%)
- February 12, 2026: actual EPS 1.25 vs estimate 1.5 (surprise -16.5%)
- October 30, 2025: actual EPS 2.9 vs estimate 1.75 (surprise +66.1%)
Expected move
Drivers
-
Past earnings
Negative
After results on July 30, 2026, the shares moved 28.4% from one close to the next, with an initial reaction of 21.3%.
- Implied move
- +3.5%
- Source
- Options chain
Reactions over its last 21 earnings
- Median move
- 3.1%
- 75th percentile move
- 7.5%
- 90th percentile move
- 15.2%
- Up / down moves
- 9 / 12
- Average up move
- +4.5%
- Average down move
- -7.3%
Monitoring and close
What Alnylam Pharmaceuticals, Inc. reported
- Status
- Finished
| Actual EPS | 16.26 |
|---|---|
| EPS estimate | 2.25 |
| EPS surprise | +623.0% |
| Revenue | $1,458 million |
| Revenue estimate | $1,434 million |
| Revenue surprise | +1.7% |
Alnylam reported Q3 2026 revenue of $1.46 billion and adjusted EPS of $16.26, reaffirmed its outlook, and expanded the nucresiran heart trial to about 2,250 patients; shares fell 19%.
Sources (15)
- Alnylam Updates Phase 3 TRITON-CM Study for Nucresiran (opens in a new tab) — fiscal.ai
- Alnylam Pharmaceuticals Reports Q3 2026 Financial Results (opens in a new tab) — fiscal.ai
- Alnylam (ALNY) Q3 2026 Earnings Call Transcript (opens in a new tab) — Yahoo
- Alnylam Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) — Yahoo
- Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction” (opens in a new tab) — Yahoo
- Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Alnylam Pharmaceuticals Q3 2026 Earnings Call Transcript (opens in a new tab) — Benzinga
- Premarket Gainers and Losers on Oct. 29, 2026 (opens in a new tab) — ChartMill
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (opens in a new tab) — Yahoo
- Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics (opens in a new tab) — Yahoo
- Alnylam: Q3 Earnings Snapshot (opens in a new tab) — Yahoo
- Alnylam reported adjusted EPS of $16.26 versus the $2.25 consensus, and sales of $1.458B, above the $1.434B estimate. — Benzinga
- Alnylam Pharmaceuticals Q3 Adj. EPS $16.26, Sales $1.458B Beat $1.434B Estimate (opens in a new tab) — Benzinga
- Alnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.275B-$5.725B vs $5.471B Est (opens in a new tab) — Benzinga
- Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating -4.8% pre-market, a move above the stock's usual reaction (about 3%). The figures overturn the prior optimistic scenario. Across our market history, in the 738 similar cases the close held that direction 87% of the time.
How the stock reacted
- Outcome
- Missed
- Consolidated
- -25.1%
- Max favorable move (MFE)
- 4.2%
- Max adverse move (MAE)
- 25.9%